Filter Results:
(482)
Show Results For
- All HBS Web (482)
- Faculty Publications (365)
Show Results For
- All HBS Web (482)
- Faculty Publications (365)
- 13 Jun 2005
- Research & Ideas
From Turf Wars to Learning Curves: How Hospitals Adopt New Technology
employed by the hospitals in which they work. The resulting social interactions between these individuals and groups within hospitals provide a fruitful setting for examining issues that are of relevance to organizations in a broader range of industries. The hospital... View Details
- 01 Mar 2005
- News
A Primer on Patents
fifteen years ago, as a doctoral candidate in Harvard’s Economics Department, Lerner was collecting data on the role of VC funding in the biotechnology industry. Before long, he also became intrigued by the concept of intellectual... View Details
- 01 Mar 2003
- News
Naina Lal Kidwai
to the global automobile industry. Biotechnology and pharmaceutical firms are emerging as international players. There are also opportunities in infrastructure investment, such as telecom, ports, roads, and airports. Please comment on... View Details
- April 1995 (Revised April 1999)
- Teaching Note
Aberlyn Capital Management TN
By: Josh Lerner
Teaching Note for (9-294-083). View Details
- March 2025 (Revised April 2025)
- Teaching Note
Moving Science: The Rowland Institute at Harvard
By: Maria Roche
Teaching Note for HBS Case No. 724-441. View Details
- 03 Aug 2010
- First Look
First Look: August 3
http://www.hbs.edu/research/pdf/11-005.pdf The Influence of Prior Industry Affiliation on Framing in Nascent Industries: The Evolution of Digital Cameras Authors:Mary J. Benner and Mary Tripsas Abstract New View Details
Keywords: Martha Lagace
- 01 Dec 1996
- News
Entrepreneurship at HBS
direct marketing, consumer products, and consulting. Following Professor Georges F. Doriot's lead, our graduates have had a major impact on the venture capital industry, which in turn financed a revolution in semiconductors, personal computers, communications, and... View Details
- 23 Jun 2003
- Research & Ideas
Historically Speaking: A Roundtable at HBS
Pharmaceutical Industries, to be published by The Free Press in 2004]. It includes a chapter on biotechnology, the next industry that will create a sea change in our lives. Spar: And biotechnology will go... View Details
Keywords: by Jim Aisner
- 24 Sep 2007
- Research & Ideas
The FDA: What Will the Next 100 Years Bring?
The U.S. Food and Drug Administration, which was created by the passage of the 1906 Federal Food and Drugs Act, regulates companies and industries accounting for one-quarter of all consumer spending, roughly $1.5 trillion worth of... View Details
- April 2024 (Revised November 2024)
- Case
Moderna: Pioneering a People Platform to Accelerate Science Innovation
By: Tatiana Sandino, Emil Dy and Samuel Grad
Moderna was founded in 2010 to explore how messenger ribonucleic acid (mRNA) could be used to create breakthrough medicines by encoding instructions for the body to create antibodies. When Stéphane Bancel (HBS 2000) took over in 2011, he bet on the potential of this... View Details
Keywords: Disruptive Innovation; Talent and Talent Management; Selection and Staffing; AI and Machine Learning; Digital Strategy; Innovation and Management; Leadership Development; Management Practices and Processes; Management Systems; Organizational Culture; Performance Evaluation; Alignment; Employee Relationship Management; Science-Based Business; Expansion; Pharmaceutical Industry; Pharmaceutical Industry; United States
Sandino, Tatiana, Emil Dy, and Samuel Grad. "Moderna: Pioneering a People Platform to Accelerate Science Innovation." Harvard Business School Case 124-091, April 2024. (Revised November 2024.)
- November 2020
- Teaching Note
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
Teaching Note for HBS Case No. 221-031. When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA)... View Details
- Spring 2014
- Article
Attracting Long-Term Investors Through Integrated Thinking and Reporting: A Clinical Study of a Biopharmaceutical Company
By: Andrew Knauer and George Serafeim
Faced with a large percentage of investors that chase short-term returns, companies could benefit by attracting investors with longer-term horizons and incentives that are more consistent with the long-term strategy of the company. The managers of most companies take... View Details
Keywords: Investing; Asset Management; Long-term Investing; Short-termism; Sustainability; Integrated Reporting; Leadership & Corporate Accountability; Pharmaceuticals; Leadership; Integrated Corporate Reporting; Investment; Business and Stakeholder Relations; Corporate Finance; Biotechnology Industry; Biotechnology Industry
Knauer, Andrew, and George Serafeim. "Attracting Long-Term Investors Through Integrated Thinking and Reporting: A Clinical Study of a Biopharmaceutical Company." Journal of Applied Corporate Finance 26, no. 2 (Spring 2014): 57–64.
- February 2010
- Background Note
Millipore Background Note
By: Elie Ofek and Natalie Kindred
This note provides background on Millipore Corporation, a global provider of products and services used primarily in the discovery, development and production of therapeutic drugs. With a track record of quickly adapting to the evolving needs of its customers,... View Details
Keywords: Organizational Change and Adaptation; Customer Focus and Relationships; Biotechnology Industry; Biotechnology Industry
Ofek, Elie, and Natalie Kindred. "Millipore Background Note." Harvard Business School Background Note 510-059, February 2010.
- July 2009
- Teaching Note
Khosla Ventures: Biofuels Strategy (TN)
Teaching Note for [809004]. View Details
- March 2009
- Teaching Note
Antegren: A Beacon of Hope (TN)
Teaching Note for [408025], [408026], [408027], and [408028]. View Details
- 2006
- Chapter
BioRisk: interleukin-2 from laboratory to market in the United States and Germany
By: Arthur A. Daemmrich
- June 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (C)
By: Sandra J. Sucher and Stacy McManus
Supplements the (A) and (B) cases. View Details
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (C)." Harvard Business School Case 603-045, June 2003. (Revised October 2004.)
- March 2002 (Revised May 2002)
- Case
Genzyme: Engineering the Market for Orphan Drugs
Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme's business model under new pressures. View Details
Keywords: Business Model; Information Technology; Market Entry and Exit; Biotechnology Industry; Biotechnology Industry
Chesbrough, Henry W., and Clarissa Ceruti. "Genzyme: Engineering the Market for Orphan Drugs." Harvard Business School Case 602-147, March 2002. (Revised May 2002.)
- September 2001
- Supplement
Millennium Pharmaceuticals, Inc. (B)
By: Stefan H. Thomke and Ashok Nimgade
Supplements the (A) case. View Details
Thomke, Stefan H., and Ashok Nimgade. "Millennium Pharmaceuticals, Inc. (B)." Harvard Business School Supplement 602-063, September 2001.
- October 2000
- Teaching Note
Kendle International Inc. TN
By: Dwight B. Crane and Indra Reinbergs
Teaching Note for (9-200-033). View Details